UNASSIGNED: The aim of this observational cohort study was to specify the risk of the @entity2067 antagonist (VKA) @entity3924 during first trimester of pregnancy, in particular to estimate the risk of @entity600 and spontaneous fetal loss. Four hundred eight pregnancies with @entity3924 exposure were compared to 1,642 pregnancies neither exposed to VKA nor to other major teratogens or fetotoxicants. There was no typical @entity1229 @entity2241 in our exposed cohort. However, the overall rate of major @entity600 was significantly increased (7.4   % vs 2.3   %; adjusted odds ratio [ORadj] 2.14; 95   % confidence interval [CI] 1.4-3.4). With early cessation until five completed gestational weeks the @entity600 risk was similar to the comparison cohort (2.4   % vs 2.3   %; ORadj 1.07; 95   % CI 0.2-3.6). With treatment duration exceeding seven gestational weeks the rate of major @entity600 increased up to five-fold (10.8   % vs 2.3   %; ORadj 5.18; 95   % CI 2.0-11.6). The overall risk of @entity2208 ( @entity2208 ) was 38.0   % vs 17.5   % in the comparison cohort (adjusted hazard ratio (HRadj) 2.9; 95   % CI 2.2-3.9). The treatment duration had a significant effect on the hazard of @entity2208 (HRadj 1.12; 95   % CI 1.01-1.25 per each additional exposure week). @entity3924 and other VKA carry an embryotoxic risk. This risk seems to be time-dependent with a steep risk increase for @entity600 and also for fetal loss after week 5. If @entity66 permits, VKA therapy should be switched to safer alternatives such as heparins immediately after early recognition of pregnancy.

Pregnancy outcome of first trimester exposure to the XXXX antagonist @entity3924 depends on duration of treatment.

@entity2208 :: ('MESH:D000022', 'Disease') :: ['SAB', 'spontaneous abortion'] @entity3924 :: ('MESH:D010644', 'Chemical') :: ['phenprocoumon', 'Phenprocoumon'] @entity66 :: ('MESH:D004194', 'Disease') :: ['maternal disease'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K'] @entity600 :: ('MESH:D000014', 'Disease') :: ['birth defect', 'birth defects'] @entity2241 :: ('MESH:D005315', 'Disease') :: ['embryopathy'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity2067 :: (MESH:D014812,Chemical) :: ['vitamin K']
